This issue begins with a substantive review of the effects of several important botanicals on enzymes that affect metabolism and transport of drugs in the body. These include the cytochrome P450 enzymes, glucuronosyltransferases, and P-glycoprotein. The effects of the botanicals on enzyme activity and on pharmacodynamics and pharmacokinetics of drugs for which interactions have been explored or noted are discussed in detail. The team of authors who contributed these articles is headed by Stacy Shord, PharmD, a board-certified oncology pharmacist and assistant professor at the College of Pharmacy, University of Illinois at Chicago. This detailed and thorough assessment of the evidence for these herb-drug interactions is an excellent resource for all concerned with this problem.
John Salerno and colleagues at the Maharishi International University are publishing in this issue a randomized controlled study on transcendental meditation and its effects on quality of life in breast cancer patients. This is a particularly interesting intervention to study in that it has been standardized and widely applied throughout the United States and other populations. This makes it potentially quite reproducible and easy to implement in a wide variety of public health-oriented programs.
The integrative cancer care team at the Dana-Farber Cancer Institute has contributed an Integrative Tumor Board concerning a "triple negative" breast cancer patient who received conventional treatment at the institute, along with an integrative consultation. The contributions that nutrition, massage, acupuncture, and yoga made to the support of this patient are outlined in detail by a team of practitioners, including the coclinical director of the Zakim Center, Dr David Rosenthal.
Gazala Khan and colleagues from the University of Michigan, MD Anderson Cancer Center, and Punisyn Pharmaceuticals have contributed an encouraging study of the effects of pomegranate on reducing invasion and motility of breast cancer cells. The pomegranate is showing ever more promise in a variety of cancers. Furthermore, the reports of different and intriguing biological effects of phytochemicals and plant extracts continue to expand our concept of the potentials of foods and supplements for improving long-term cancer outcomes.
Phyllanthus amarus is an Indian medicinal plant that has been explored for a great many medicinal uses, including studies of its effect on hepatitis. The study in this issue by Kuzhuvelil Harikumar of Virginia Commonwealth University and colleagues at the Amala Cancer Research Center in India documents increase in the lifespan of mice with virally induced leukemia and decrease in the progression of the leukemia as well. A demonstration of the decrease of infiltration of leukemic cells into the spleen is a particularly vivid demonstration of the potential effects of this plant drug.
Pankaj Singh and colleagues at the Institute of Nuclear Medicine and Allied Sciences in India report the effects of Podophyllum hexandrum on radioresistance of hepatoma cell lines. With detailed biochemical study of the effect of P hexandrum extract on induction of p53 and on cell cycle, they conclude that this species has the potential to differentially protect normal and cancer cells during radiotherapy. P hexandrum is well known as a source for podophyllotoxin, the basis of the semisynthetic chemotherapy drug etoposide. It is certainly interesting to see that it may also contribute to fighting cancer through effects on radiotherapy.
Alstonia scholaris, an alkaloid-containing tree used widely in Asia as an alternative to quinine, has been studied by Pradeep Goyal and colleagues in the DMBA skin carcinogenesis system in mice. Although the alkaloids of this plant have been studied for anticancer effects in the past, it is, interestingly enough, the enzymatic and nonenzymatic antioxidant activities that appear to inhibit skin carcinogenesis with DMBA. Lipid peroxidation, glutathione, superoxide dismutase, and catalase were all affected by A scholaris in this study.
One of the concerns of integrative therapy is the amelioration of cancer treatment side effects. A case study in this issue by Yong-Song Guan discusses surgical treatment of one such side effect, radiation-induced fibrosis induced by gammaknife therapy. Rather than being a straightforward demonstration of treatment, this case proved to be a demonstration of the pitfalls of such surgical repair, owing to the deceptive impressions offered by the images used to localize the area needing treatment.
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A combination of innovative experimental therapies and photodynamic and sonodynamic therapies is used in the final article of this issue, a short case series from Xiaohuai Wang and colleagues from Guangzhou, China. Sonodyamic therapy resembles photodynamic therapy in that it uses localized activation of specialized chemical compounds; however, rather than using light as an activator, ultrasound is used. This provides an advantage in reaching areas of the body that light cannot access. The combination of the 2 therapies further expands the range of these therapies. Sonodynamic therapy has received substantial attention from Chinese researchers in recent years. This issue thus "covers the map" from ancient herbal therapies to innovative molecular applications such as sonodynamics and from the pharmacokinetics of drug interactions to the applications of meditation. Integrative Cancer Therapies is pleased to be able to present such a wide-ranging series of articles, because integrative care today is certainly characterized by its diversity. Our next issue, however, will narrow its focus to a more specialized aspect of integrative care-the effects of disruption of the circadian light-dark system on cancer. We will be publishing the proceedings of the New York Academy of Sciences conference, "Circadian Disruption and Cancer," held on June 19, 2009.
